Market Overview:

The Global Small Molecule Prefilled Syringes Market Was Valued At USD 17.41 Million In 2021, And USD 28.18 Billion By 2030 With CAGR Of 5.5% Over The Forecast Period From 2022-2030.

Prefilled syringes are basically just single-dose containers of parenteral medicine that come with a needle. Prefilled syringes make patients safer because they reduce the chance of needle sticks and harmful product exposure that can happen when medication is drawn from vials.

A Small Molecule Prefilled Syringes is a drug whose small molecular weight makes it easy for it to get into cells. Once it gets inside the cell, it works with other molecules like proteins to kill the cancer cell. This is different from drugs that have a high molecular weight, which makes it hard for them to get into cells. Small molecule prefilled syringes are prefilled syringes that have already been filled with small molecule drugs. As an alternative to capsules and tablets, prefilled syringes with small molecules can be used to give a dose. Solutions of the active ingredients in drugs are put into empty syringes made of glass, polymer, or plastic. There are prefilled syringe delivery systems for drugs in categories like cardiology, neurology, adjuvants, and painkillers. Because the drug goes straight into the bloodstream, small molecule prefilled syringes work faster than syringes and tablets.

COVID-19 Impact:

At the end of December, a COVID-19 outbreak began in the Chinese city of Wuhan in the Hubei province. This virus is called SARS-CoV-2, which stands for severe acute respiratory syndrome coronavirus 2. Due to the lower risk of needle-stick injuries, more people are choosing prefilled syringes over glass ampoules or any other extra needles. So, to make more COVID-19 vaccine, the people who make it have increased the number of prefilled syringes they can make at once. For example, the U.S. government has agreed to pay syringe makers $138 million to help them make 100 million prefilled syringes for COVID-19 vaccines by the end of 2020.

Due to the rise in demand for home-based health care services, market players have spent more on raw materials and resources. Health care professionals have responded to new and different ways to provide the right amount of care by using telemedicine, which helps to reduce face-to-face interactions. During the COVID-19 pandemic, the increased role of community and individual pharmacists in managing chronic conditions and promoting medication adherence has made healthcare systems less stressed. Overall, the effect of COVID-19 on the market for prefilled syringes was seen to be pretty good. This was due to the fact that more people wanted prefilled syringes instead of glass ampoules or other needles. Due to the rise in demand for home-based healthcare services, market players have also put more money into raw materials and other resources.

Market Dynamics:

Market Trends:

On the global life science market, biologics and biosimilars are quickly replacing medicines made from chemicals. Biologics are great for targeted delivery and increasing inclination because they are less likely to interact with other drugs. Manufacturers of pharmaceuticals and packaging are under pressure to come up with better ways to close containers and deliver drugs because more biologics are being used to treat long-term illnesses. Because of this, the number of people using these syringes to safely give biologics and biosimilars has grown by a lot. For example, the Central Drugs Standard Control Organization says that 98 biosimilars have been approved in India (CDSCO).

Driving Factors:

• The Growing Prevalence of Health Complications 

Heart diseases like cardiac arrest, coronary artery disease, and high blood pressure have become more common by more than 17 percent in the last ten years. Heart attacks kill a lot of people in the US and other countries with large numbers of overweight people. A report says that nearly 659,000 Americans die of heart attacks every year. Also, the increasing number of older people has led to a rise in arthritis cases. In 2021, more than 350 million people around the world had arthritis. The problem is likely to get worse because soon there will be 2 billion people over the age of 65. In addition, people's busy lives are causing them to have more stress and depression, which is also helping the market grow.

• Growing Health alternatives among the People

As people's living standards rise, they are less likely to react and more likely to take the lead. Many homes now keep a good supply of generic medicines like painkillers and other medicines that could help them in an emergency. Also, the fact that prefilled syringes can be used by themselves has caught the attention of millions of people all over the world. So, the growing demand for ready-to-use and self-administering prefilled syringes has become a key factor in the growth of the market. The market has also grown because infrastructure is getting better in developing countries, people are becoming more tech-savvy, and digitalization is happening quickly. For example, most smartphone users in the world live in China and India. In 2021, China had more than 900 million users, while India had more than 420 million. The number is likely to go up, which will add to the growth of the market.

• Safety Features to Cushion the Market Growth

Also, prefilled syringes make patients safer by reducing the risk of needle sticks and exposure to harmful products that can happen when drawing medication from vials. This will help the market grow in the coming years.

In addition, the growing number of biologics and biosimilars in the pharmaceuticals market, the high demand for advanced drug delivery devices for accurate dosing, and the increasing use of self-injecting parenteral devices are all expected to help the market grow.

• Ease in Usage Will Boost the Growth

They are easy to use because of how convenient and safe they are to use. As a result, there has been a rise in the demand for self-injection and related devices, and the fact that they are easy to use should also help the market grow.

Restraining Factors:

• Risk of Injuries

According to the information we have, a lot of needle stick injuries are caused by more people using prefilled syringes that don't have safety features built in. This factor is likely to stop the growth of the market.

• Availability of Cheaper Alternatives

Prefilled syringes are much more expensive to buy than disposable syringes because they have to be made with a lot of expensive parts.

In the past, injections were invasive and painful, which was the main reason why patients preferred other ways to take drugs, such as by mouth, skin, or nose. The most common way to give a drug is through the mouth. This is because it is easy to use, convenient, cheap, safe, and acceptable. Because of the above reasons, more and more people around the world are using alternative ways to give drugs. For example, the development of cheaper ways to deliver insulin, like Pfizer's Exubera (inhalable insulin) and Medtronic's Veo insulin pump (also inhalable insulin), is making injectable insulin less popular. At the moment, injections are the most common way to give insulin, so insulin injections are a big market for injectable drug delivery technologies. But the development of inhalable insulin is likely to have a big effect on the growth of this market, since nasal drug delivery is painless and easy for patients to do. Also, the growth of injectable technologies is likely to slow down in the coming years because GlaxoSmithKline and Bayer are working on new ways to treat diseases, like anemia, that don't involve injections.

Opportunities:

• Growing Awareness and Supportive Regulations 

Also, it is thought that supportive government regulations, especially needle stick laws, will create profitable opportunities for the market. As both patients and medical professionals learn more about the benefits of prefilled syringes, the market will have even more chances to grow.

• Growing the Healthcare Infrastructure across Emerging Market

Emerging countries still don't have enough money for health care, which hurts access, quality, and, in the end, the health of the people who live there. The World Bank says that about 400 million people, mostly in Africa and South Asia, don't have access to basic health care services. Also, funding gaps have been caused by rising medical inflation, which is the cost of medical treatments, and a rise in non-communicable lifestyle-related diseases like cancer, diabetes, and cardiac syndromes.

A report by the Geneva Association says that in the last 20 years, the share of total global spending on healthcare as a percentage of GDP has gone from about 8% to almost 10%, or about USD 8 trillion per year. This is because the cost of medical care is going up, there are more options for treatment, and customers want more. Also, the Global Burden of Disease Health Financing Collaborator Network predicts that global spending on health will almost triple to USD 24 trillion by 2040, with upper-middle-income countries showing the fastest growth at an average of 5.3% per year. This growth could be explained by the fact that GDP is still growing, the middle class is getting bigger, and the government is spending more money.

Challenges:

• The Gap between Demand and Supply and Reduced Income Because of Pandemic

The precautionary lockdowns put in place by governments around the world to stop the spread of the virus have had a terrible effect on the growth of the prefilled syringe small molecule market. Due to the pandemic, a lot of people had to quit their jobs or were fired. Because of this, production has slowed down because there aren't as many people working. Still, companies couldn't do business because they didn't have enough raw materials. Also, because many people have lost their jobs, they have less money to spend on things they want.

Strategic Development:

• In December 2020 - Becton, Dickinson and Company (BD), a world leader in medical technology, has said it will invest $1.2 billion over four years starting. This investment is being made to increase manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) at its six global manufacturing locations and to open a new manufacturing facility in Europe. By the end of 2023, the new factory should be up and running in Europe.
• In December 2021 - Roche Holding, a large healthcare company based in Basel, Switzerland, announced that it had successfully bought the Berlin, Germany-based biotech company TIB Molbiol. The money details of the deal were kept secret. But Roche's ability to develop quick tests will be improved by the acquisition.
• In September 2021 - "Sanofi," a well-known healthcare company based in Paris, France, said it had reached a deal with "Kadmon Holdings," a biopharmaceutical company based in New York, United States. Sanofi said that it will pay a total of $1.9 billion ($9.50 per share) to finish the process.
• In June 2019 - The company McKesson Corporation, which is based in Texas and is known for its services and pharmaceutical supplies, said that it had successfully bought the "Echo" medicine management app, which helps patients remember "when to take medicine." The company did not say how much money was involved in the deal.

Key Vendors:

Top market players are

• Pfizer

Pfizer is a top biopharmaceutical company that focuses on research. We use science and our global resources to come up with new therapies that save lives and make them much better. Every day, people who work for Pfizer in both developed and developing markets work to improve health, prevention, treatments, and cures for the most feared diseases of our time.

• Sanofi S.A.

France is home to the health care company Sanofi SA. The company focuses on what patients need and researches, develops, makes, and sells therapeutic solutions.

• Mylan N.V.

Mylan NV is a healthcare company that makes medicines. The company develops, licenses, makes, markets, and sells generic, branded generic, and specialty pharmaceutical products. It does business in the following parts of the world: Europe, North America, and the rest of the world.

• Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. (Teva) finds, develops, makes, and sells generic and specialty medicines. The company makes specialty medicines that are used to treat disorders of the central nervous system (CNS), cancer, lung disease, skin disease, women's health, and other diseases. It sells generic medicines in capsules, tablets, injectables, liquids, inhalants, creams, and ointments, among other ways to take them.

• Becton Dickinson, and Co Company

Becton Dickinson and Company (BD) is a company that makes and sells medical instruments, reagents, and devices. Its main products are syringes and pen needles, intravenous catheters, infusion pumps and disposables, automated medication dispensing and supply management systems, pre-filled drug delivery systems, respiratory ventilation and diagnostic equipment and consumables, products for the safe collection and transport of diagnostic specimens, instruments and reagent systems to detect a range of infectious diseases and cancers, and clinical research tools.

• Fresenius Kabi AG

Fresenius Kabi is a global healthcare company that focuses on making life-saving medicines and technologies for infusion, transfusion, and clinical nutrition. The products and services of the company are used to treat and care for people who are critically or chronically ill. Its product line includes very complicated biopharmaceuticals, clinical nutrition, medical technologies, and generic I.V. drugs.

Segmentation Analysis:

The market is segmented on the basis of type, material, design, end-user and region.

By Type Outlook:

The conventional prefilled syringes and the safety prefilled syringes are two types of the prefilled syringes market. The Safety Prefilled Syringes segment led the growth of the market in 2022, and it is expected to be the segment with the fastest growth from 2022 to 2030. Part of the stress on hospitals is lessened by the growing number of older people around the world, the development of biological medicines for people with chronic diseases, and the outsourcing of low-risk medical procedures for chronic patients.

• Conventional prefilled syringes
• Safety prefilled syringes

By Material Outlook:

The Prefilled Syringes market is divided into Glass Syringes, Oil Siliconized Syringes, Baked Silicone Syringes, and Plastic Syringes based on the material they are made of. In 2022, most of the market share for prefilled syringes was held by the glass syringes segment. Glass syringes are the standard for prefilled syringes right now. Glass syringes are easy to use, and doctors can check them for particles that could make them dirty. Glass is a good choice because it is clear and inert, which makes sure that the dose is pure. But glass syringes are less likely to be used in the market for prefilled syringes because consumers want safer products that let them give themselves medicine and because glass is more likely to break during shipping.

• Glass Syringes
• Oil Siliconized Syringes
• Baked Silicone Syringes
• Plastic Syringes

By Design:

The Prefilled Syringes market data includes Single-Chamber Prefilled Syringes, Dual-Chamber Prefilled Syringes, and Customized Prefilled Syringes. The Single-Chamber Prefilled Syringes segment brought in the most money for the Prefilled Syringes market in 2022, and it is expected to be the segment with the fastest growth from 2022 to 2030. Using single-chamber prefilled syringes instead of vials has many benefits, such as getting the most out of the API with less overfill, reducing the amount of materials needed, wasting less drug in clinical studies, and making it easier to store and throw away. Also, more and more people are using self-administered parenteral medications because they are easier to use and because prefilled syringes are helpful.

• Single-Chamber Prefilled Syringes
• Dual-Chamber Prefilled Syringes
• Customized Prefilled Syringes

By End-User:

Based on End-user, the Prefilled Syringes market data includes Hospitals/Clinics and Ambulatory Surgical Centers. The Hospitals/Clinics segment dominated the Prefilled Syringes market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Due to an increase in the number of patients admitted with cancer, diabetes, and cardiovascular disorders. Due to their numerous uses, hospitals are the main consumers of these syringes. The market is also anticipated to rise due to increased attention paid to developing healthcare infrastructure in emerging nations in Asia, the Pacific, and Africa. This segment's growth is predicted to be negatively impacted by the rising trend of self-care and the availability of gadgets that allow fewer visits to healthcare providers.

• Hospitals & Clinics
• Ambulatory Surgical Center

Regional Insights:

The global Small Molecule Prefilled Syringes market has been looked at in different parts of the world, including North America, Latin America, the Middle East, Asia-Pacific, Africa, Europe, and India. In the near future, the global Small Molecule Prefilled Syringes region will be the market leader.

Over the next few years, North America is expected to have the largest share of the global market for small molecule prefilled syringes. This is due to the growing number of non-organic growth strategies, such as partnerships between market players. In April 2019, for example, Schreiner MediPharm, a global provider of specialty pharmaceutical labeling solutions based in Germany, announced a partnership with B. Braun Medical, a company that makes medical and pharmaceutical devices. Schreiner MediPharm's label-integrated Needle-Trap system was used to help B. Braun get its prefilled syringe of Heparin Sodium injection on the U.S. market. This was its unique selling point (USP).

Also, because market players are investing in manufacturing units to grow their businesses, the global small molecule prefilled syringes market is expected to grow a lot in Europe over the next few years.

For example, in December 2020, BD (Becton, Dickinson and Company), a leading global medical technology company, announced plans to invest about US$ 1.2 billion over four years to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across its six global manufacturing locations and add a new manufacturing facility in Spain.

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Scope of Report:

Conclusion:

• This report gives a detailed quantitative analysis of the current trends and forecasts for the prefilled syringes market from 2020 to 2030. This helps to find the best opportunities in the market.
• An in-depth prefilled syringes market analysis looks at the market in different regions. This is meant to give a clear picture of the current trends so that stakeholders can make plans for each region.
• The global prefilled syringes market is analyzed in depth in terms of the factors that drive and slow its growth.
• A thorough analysis of different regions gives companies information that should help them plan their business moves in a strategic way.
• In this report, profiles of the most important players in the market are given, and their strategies are carefully looked at. This helps readers understand the competitive landscape of the prefilled syringes market.